Insider Selling: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Insider Sells 8,305 Shares of Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) insider Greg Keenan sold 8,305 shares of the stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $8.23, for a total transaction of $68,350.15. Following the completion of the sale, the insider now owns 153,484 shares of the company’s stock, valued at approximately $1,263,173.32. This trade represents a 5.13 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Greg Keenan also recently made the following trade(s):

• On Monday, March 3rd, Greg Keenan sold 12,239 shares of Aurinia Pharmaceuticals stock. The shares were sold at an average price of $8.00, for a total transaction of $97,912.00.

Aurinia Pharmaceuticals Trading Down 0.5 %

Shares of AUPH stock opened at $8.15 on Friday. The company has a 50 day moving average of $8.08 and a 200-day moving average of $7.88. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a 12-month low of $4.71 and a 12-month high of $10.67. The firm has a market cap of $1.12 billion, a P/E ratio of -54.33 and a beta of 1.26.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Several large investors have recently modified their holdings of AUPH. Tang Capital Management LLC increased its stake in shares of Aurinia Pharmaceuticals by 16.6% during the 4th quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company’s stock worth $75,697,000 after purchasing an additional 1,200,000 shares during the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in Aurinia Pharmaceuticals in the 4th quarter valued at approximately $9,662,000. Point72 Asset Management L.P. purchased a new position in Aurinia Pharmaceuticals in the 4th quarter valued at approximately $7,630,000. Lazard Asset Management LLC grew its stake in Aurinia Pharmaceuticals by 341.9% in the 4th quarter. Lazard Asset Management LLC now owns 596,389 shares of the biotechnology company’s stock valued at $5,355,000 after buying an additional 461,430 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in Aurinia Pharmaceuticals in the 3rd quarter valued at approximately $3,330,000. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 19th.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.